Intracoronary cardiosphere-derived stem cell therapy - Capricor

Drug Profile

Intracoronary cardiosphere-derived stem cell therapy - Capricor

Alternative Names: CAP-1001; CPI-003; CPI-003 - Capricor

Latest Information Update: 03 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Capricor
  • Developer Capricor Therapeutics; Cedars-Sinai Health System; Johns Hopkins University School of Medicine
  • Class Antineoplastics; Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 31 Dec 2013 No development reported - Phase-I for Myocardial infarction in USA (Intracoronary)
  • 21 Nov 2013 Nile Therapeutics has merged with Capricor to form Capricor Therapeutics
  • 16 Aug 2011 Phase I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top